Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

Jian Yan; Dawn K. Reichenbach; Natasha Corbitt; David A. Hokey; Mathura P. Ramanathan; Kibwei A. McKinney; David B. Weiner; Duane Sewell

doi:10.1016/j.vaccine.2008.10.078

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

Jian Yan
, Dawn K. Reichenbach
, Natasha Corbitt
, David A. Hokey
, Mathura P. Ramanathan
, Kibwei A. McKinney
, David B. Weiner
, Duane Sewell

Research output: Contribution to journal › Article › peer-review

74 Scopus citations

Abstract

Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.

Original language	English (US)
Pages (from-to)	431-440
Number of pages	10
Journal	Vaccine
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.vaccine.2008.10.078
State	Published - Jan 14 2009
Externally published	Yes

Bibliographical note

Funding Information:
This work was supported in part by NIH grants awarded to Dr. David B. Weiner, NCI grant K08 CA097218 awarded to Dr. Duane Sewell.

Keywords

DNA vaccine
E6 and E7 protein
HPV-16

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.vaccine.2008.10.078

Find It

Find It at U of M Libraries

Cite this

@article{52915f0101224648b9efc0259a79ed42,

title = "Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen",

abstract = "Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100\% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.",

keywords = "DNA vaccine, E6 and E7 protein, HPV-16",

author = "Jian Yan and Reichenbach, \{Dawn K.\} and Natasha Corbitt and Hokey, \{David A.\} and Ramanathan, \{Mathura P.\} and McKinney, \{Kibwei A.\} and Weiner, \{David B.\} and Duane Sewell",

note = "Funding Information: This work was supported in part by NIH grants awarded to Dr. David B. Weiner, NCI grant K08 CA097218 awarded to Dr. Duane Sewell. ",

year = "2009",

month = jan,

day = "14",

doi = "10.1016/j.vaccine.2008.10.078",

language = "English (US)",

volume = "27",

pages = "431--440",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

AU - Yan, Jian

AU - Reichenbach, Dawn K.

AU - Corbitt, Natasha

AU - Hokey, David A.

AU - Ramanathan, Mathura P.

AU - McKinney, Kibwei A.

AU - Weiner, David B.

AU - Sewell, Duane

N1 - Funding Information: This work was supported in part by NIH grants awarded to Dr. David B. Weiner, NCI grant K08 CA097218 awarded to Dr. Duane Sewell.

PY - 2009/1/14

Y1 - 2009/1/14

N2 - Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.

AB - Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.

KW - DNA vaccine

KW - E6 and E7 protein

KW - HPV-16

UR - https://www.scopus.com/pages/publications/57649210510

UR - https://www.scopus.com/pages/publications/57649210510#tab=citedBy

U2 - 10.1016/j.vaccine.2008.10.078

DO - 10.1016/j.vaccine.2008.10.078

M3 - Article

C2 - 19022315

AN - SCOPUS:57649210510

SN - 0264-410X

VL - 27

SP - 431

EP - 440

JO - Vaccine

JF - Vaccine

IS - 3

ER -

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this